CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Hybio Pharmaceutical Co Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Hybio Pharmaceutical Co Ltd
Middle Section
Hi-tech Industry Zone, Nanshan District
Phone: +86 75526588036p:+86 75526588036 SHENZHEN, GNG  518110  China Ticker: 300199300199
Business Summary
Hybio Pharmaceutical Co., Ltd. is a China-based company principally involved in the development, manufacture and distribution of chemical synthetic polypeptide pharmaceuticals. The Company’s products include polypeptide preparations, polypeptide active pharmaceutical ingredients (APIs) and customer polypeptide, among which the preparation products include thymopentin for injection, somatostatin for injection, desmopressin for injection and terlipressin for injection, among others. Through its subsidiaries, the Company's newly added products are pharmaceutical packaging products, medical devices and solid products. The Company is also engaged in provision of related technological services.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202312/31/2022Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
2833 Medicinal chemicals and botanical products
3842 Orthopedic, prosthetic, and surgical appliances and supplies

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board ShaoguiZeng 50
Executive President, Director PinxiangYu 40 1/1/2021 1/1/2021
Vice Chairman of the Board ShaoqiangZeng 50
8 additional Officers and Directors records available in full report.

General Information
Number of Employees: 975 (As of 12/31/2022)
Outstanding Shares: 883,241,336 (As of 9/30/2023)
Shareholders: 60,840
Stock Exchange: SHE
Fax Number: +86 75526588022


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, April 26, 2024